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Abstract
Progressively sophisticated understanding of cellular and molecular processes that contribute to age-related physical deterioration is being
gained from ongoing research into cancer, chronic inflammatory syndromes and other serious disorders that increase with age. Particularly
valuable insight has resulted from characterization of how senescent cells affect the tissues in which they form in ways that decrease an
organism’s overall viability. Increasingly, the underlying pathophysiology of ageing is recognized as a consequence of oxidative damage.
This leads to hyperactivity of cell growth pathways, prominently including mTOR (mammalian target of rapamycin), that contribute to a
build-up in cells of toxic aggregates such as progerin (a mutant nuclear cytoskeletal protein), lipofuscin and other cellular debris, triggering
formation of senescent cellular phenotypes, which interact destructively with surrounding tissue. Indeed, senescent cell ablation dramati-
cally inhibits physical deterioration in progeroid (age-accelerated) mice. This review explores ways in which oxidative stress creates age-
ing-associated cellular damage and triggers induction of the cell death/survival programs’ apoptosis, necrosis, autophagy and
‘necroapoptophagy’. The concept of ‘necroapoptophagy’ is presented here as a strategy for varying tissue oxidative stress intensity in ways
that induce differential activation of death versus survival programs, resulting in enhanced and sustained representation of healthy func-
tional cells. These strategies are discussed in the context of specialized mesenchymal stromal cells with the potential to synergize with
telocytes in stabilizing engrafted progenitor cells, thereby extending periods of healthy life. Information and concepts are summarized in a
hypothetical approach to suppressing whole-organism senescence, with methods drawn from emerging understandings of ageing, gained
from Cnidarians (jellyfish, corals and anemones) that undergo a unique form of cellular regeneration, potentially conferring open-ended life-
spans.
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Cellular and molecular features of
senescence
Introduction: cellular basis for ageing and
preliminary intervention strategies
Historical perspective
The phenomenon of physical deterioration with advancing age is a
common feature of all multicellular life, with each plant or animal spe-
cies exhibiting characteristic rates of decline as a normally occurring
element of its developmental program. Here, the term ‘apparent’ is
used because the existence of a specific genetic mechanism selected
by evolution to limit the maximal lifespan of an individual – also
termed a ‘longevistat’ – is an ongoing subject of debate [1].
Ageing is a complex and fascinating process that has been the
focus of intense efforts to understand and counteract throughout
most of human history. Until the 20th century, such initiatives were
entirely in the domain of cultural mythology. The most famous of
these in Western tradition was the pursuit of a ‘Fountain of Youth’ by
the Spanish conquistador Juan Ponce de Leony Figueroa [2].
Advances in medical technology and rapid increases in under-
standing of cellular and molecular biology have stimulated increas-
ingly sophisticated efforts to define ageing at a level that may allow
interventions resulting in lifespan extension. Unfortunately, although
enormous gains have been made in the development of therapies for
age-associated diseases, such as chronic inflammatory disorders,
efforts to decrease rates of physical ageing as a whole have been
hampered by an inability to fully characterize the underlying mecha-
nisms of the ageing process. Thus, clear characterization of physical
ageing has been difficult due to the lack of a clear case definition that
may lead to intervention strategies.
Early characterizations of cellular ageing – the ‘Hayflick
Limit’
The underlying complexity of age-related physical decline has led
many in the scientific community to conclude that the process may
represent a general deterioration of cellular function, with insufficient
unifying features to allow for definitive interventions. Interestingly,
although recent characterization of cellular senescence seems to sup-
port such conclusions, ambiguity exists in the interpretation of ongo-
ing studies in this field [3]. This work will be discussed in section I-2
of the present review.
Arguments that ageing is too intricate a process to effectively
counteract are diminished to some degree by the implications of
studies in the 1960s by Hayflick et al. demonstrating the replicative
limits to eukaryotic cells in culture [4]. This phenomenon, known as
the Hayflick limit, is defined as the average maximum number of dou-
blings a population of normal cells is capable of undergoing before its
replicative potential is lost. This maximum in vitro doubling capacity
was observed to vary, depending on the median lifespan of the spe-
cies from which cells used to establish the culture were taken. For
example, cultures of human foetal cells are observed to double 40–60
times before losing proliferative potential [4], whereas cultures estab-
lished from mice, a short-lived species, double a maximum of approx-
imately 15 times [5], and cells from Galapagos tortoises, which live
well over a century, demonstrate an upward in vitro doubling limit of
around 110 times in culture [6].
Significantly, it has also been observed that cell cultures derived
from patients afflicted with progeroid diseases, in which features of
rapidly accelerated ageing are a primary symptom, exhibit far lower
Hayflick limits than cells from normal individuals [7]. The strong posi-
tive correlation between cell lineage doubling potential (as defined by
the Hayflick limit and by longevity of a particular individual) may imply
the presence of a normally occurring physiological process acting to
limit maximum lifespan within a particular species. This is the defini-
tion of a ‘longevistat’ as discussed in a review by Dale Bredesen at
the Buck Institute for Age Research, at the University of California in
San Francisco [1], which examines evidence for and against the exis-
tence of such a process, particularly the contribution of cellular
senescence to physical ageing [1]. One implication of the correlation
between the Hayflick limit of cells in culture and the median lifespan
of the species from which the cells were taken is that, if genetically
determined mechanisms for lifespan limitations exist, it may be pos-
sible to characterize their underlying features and then to intervene at
some point in their normal function in ways that result in lifespan
extension.
Life expectancy versus median lifespan
It is important to distinguish between life expectancy and lifespan.
Average life expectancy is the length of time an individual within a
population of organisms may be expected to survive when disease,
accidents, predation and other environmental stressors are factored
in. Conversely, median lifespan is a measure of the time an organism
is expected to survive in the complete absence of environmental
stressors [8, 9]. The objective of age-intervention initiatives is to
make use of cutting-edge technology to extend median lifespan sig-
nificantly in excess of the normal range for a particular species.
Telomere length: correlation between telomere erosion and
Hayflick limit in vitro
Studies of changes in nuclear chromatin organization occurring dur-
ing propagation of cell lines have revealed what may constitute ele-
ments of a longevistatic process in multicellular organisms. The
replicative potential of a particular cell lineage has been observed to
correlate with the length of chromosome tips, called telomeres. These
structures, which contain non-coding DNA, are shortened each time a
cell divides, and after a finite number of divisions, become critically
shortened, signalling a cell to stop dividing [10]. The Hayflick limit
may thus be defined on a cellular morphological basis as the number
of divisions necessary to critically deplete telomeres.
Cellular immortality, telomerase activity and telomere
length
The aforementioned Hayflick phenomenon may offer insight into
strategies for intervention in age-related physical deterioration of an
organism based on a major feature of cell division: telomere length.
For example, treatment of human fibroblasts in vitro with carnosine, a
dipeptide antioxidant occurring naturally in vertebrate brain and mus-
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cle, decreases telomere erosion rates during cell division and
increases the Hayflick limit of treated cultures [11, 12]. An even more
potent approach to preserving telomere integrity and maintaining
genomic stability of a cell is offered by specifically amplifying expres-
sion of telomerase, an enzyme that normally repairs telomeres [13].
The role of telomerase during progressive cell division activity is
shown via a diagram in Figure 1.
Initially, chromosome telomere length and structural integrity in
eukaryotic cells derived from foetal tissue are maintained by high lev-
els of telomerase. The activity of this enzyme progressively decreases
with each cycle of cell division, resulting in greatly shortened telo-
meres, decreased organization of chromatin and deleterious effects,
including cell cycle arrest and cellular senescence [3, 13, 14].
Sustained up-regulation of telomerase potentially enables unlim-
ited replicative capacity for a cell [13]. Indeed, telomerase activity is
significantly diminished in cells nearing their Hayflick limit both
in vivo and in vitro [3, 13]. Interestingly, multi-organ deterioration in a
telomerase-deficient mouse strain that underwent greatly accelerated
physical ageing was completely reversed by induction of high activity
levels of the enzyme. In these experiments, mice exhibiting physical
age near the end of the typical lifespan for this strain were restored to
full youthful vigour [14].
Unfortunately, cellular immortalization, including sustained high
telomerase activity, is an intrinsic element of carcinogenic transfor-
mation of a cell [15–17]. Moreover, as a major feature of virtually all
tumour cells is the absence of replication-associated telomere short-
ening and abolition of the Hayflick limit, a major anticancer strategy
currently being pursued is the identification of telomerase inhibitors
that restore progressive decrease in telomere length with cell division,
thus causing tumour cells to die upon reaching their Hayflick limit.
Limits to use of in vitro outcome in design of age-
intervention strategies
Attempts to identify functional correlations between the Hayflick limit
of cultured cells and whole-organism lifespan reveal major paradoxes
in efforts to develop strategies for intervention in the ageing process
based on outcome of in vitro studies of cellular ageing. Extension or
abolition of the Hayflick limit by sustained high telomerase activity in
a particular cell line has value in ongoing characterizations of ageing
on the cellular level, particularly because it may be induced in any
modern biomedical laboratory. Nevertheless, clinical use of this phe-
nomenon in age-intervention strategies must be approached with
extreme caution as sustained high telomerase activity is a key ele-
ment of carcinogenic transformation [16, 17]. For this reason, strate-
gies that may extend the replicative potential of cells in a living
organism carry a high risk of cancer formation unless countermea-
sures are employed in such procedures to decrease the risk of carci-
nogenesis. Approaches for doing this are explored in section III-3 of
the present review.
Another limitation to fibroblast use of in vitro data in the design
of animal or human age-intervention strategies is that the behaviour
of cells in culture differs substantially from their function as ele-
ments of living tissue. In vitro models also suffer from weak rele-
vance to whole-organism ageing. For instance, although some
investigators have reported that cells taken from elderly human
beings exhibit lower replicative potential than those taken from
younger volunteers [18], subsequent evaluation of methodologies
used to draw these conclusions cast doubt on their validity [19].
An additional pitfall for broad application of in vitro data is that
cells exhibiting senescent phenotypes have been detected in vivo,
but without the characteristic shortening of telomeres characteristic
of cultured cells at their Hayflick limit [20]. Such cellular pheno-
types may arise from healthy cells when subjected to stress that
damages their DNA in ways that fail to activate cell death programs
and potentially result in carcinogenic transformation. Cells sustain-
ing such damage undergo replicative arrest, preventing their pro-
gression into cancers, but also develop a senescent phenotype
through the process of stress-induced premature senescence
(SIPS), that express products, especially mediators of inflamma-
tion, which may impair healthy tissue function, promote carcino-
genesis in neighbouring cells and generally contribute to disease-
and age-associated whole-organism deterioration [3, 21, 22].
Young, undamaged cells express products and perform functions
that contribute to healthy homoeostasis. Old cells and damaged
cells that have developed a senescent phenotype affect surrounding
tissue in ways that contribute to age-associated deterioration,
including dysregulated inflammation and cancer [3, 21]. The influ-
ences on an organism of young, undamaged cells versus stressed
cells that become senescent and aged senescent cells (cells which
may have reached their Hayflick limit) are outlined by the illustra-
tion shown in Figure 2, below.
If the limitations implied by the aforementioned observations are
understood and taken into account in the development of research
strategies, cell culture models may nevertheless be used as a very
potent tool in designing experiments with expected outcome relevant
Fig. 1 Telomerase and cell division-dependent decrease in telomere
length. Chromosome telomere length and structural integrity in eukary-
otic cells derived from fetal tissue are initially maintained by high levels
of telomerase. Activity of this enzyme progressively decreases with each
cycle of cell division, resulting in greatly shortened telomeres,
decreased organization of chromatin and deleterious effects on cells,
including cell division cycle arrest and cellular senescence (Campisi,
2005; Feng et al., 1995; Jaskelioff et al., 2011).
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to whole-organism ageing. Indeed, cell culture models that incorpo-
rate SIPS cells and other senescent cellular phenotypes have provided
evolving unprecedented understanding of how cellular senescence
contributes to age-associated deterioration of tissues and whole
organisms [3].
Effect of eliminating senescent cells on age-associated
pathologies in progeroid mice
In November 2011, investigators at the Mayo Clinic College of Medi-
cine in Rochester, Minnesota reported that selective ablation of
senescent cellular phenotypes from progeroid (age-accelerated) mice
significantly delayed onset of age-related physical deterioration and
decreased severity of established degenerative symptoms in aged ani-
mals [23]. These studies utilized a sub-strain of the BubR1 progeroid
mouse bearing INK-ATTAC, a drug-inducible transgene, designed to
respond to drug treatment by elimination of cells expressing the
tumour suppressor protein p16Ink4, which is a biomarker for senes-
cent cells and a critical contributor to their emergence through elimi-
nation of proliferative capability [23]. When compared with untreated
mice, drug-treated animals in which significant attrition of senescent
cells had occurred were substantially healthier. Age-related pheno-
typic parameters that were used as a basis for this observation
included: incidence of lordokyphosis and cataracts; mean skeletal
muscle fibre diameters measured in 10-month-old mice; physical sta-
mina; body and fat depot weights of 10-month-old mice; fat cell diam-
eters in 10-month-old mice; dermis and subdermal adipose layer
thickness of 10-month-old mice; and several other major health-
related features that deteriorate with age and at a very high rate in
the BubR1 progeroid strain, used as a model in the aforementioned
studies [23].
Inhibition of accelerated ageing in mice by telomerase
reactivation – 2011 Dana Farber studies
Another striking example of how insight gained from in vitro stud-
ies has contributed to the development of approaches to suppres-
sion of age-associated pathologies in animals is provided by the
study with age-accelerated mice conducted by Jaskelioff et al.,
described above [14]. This very intriguing research, recently con-
ducted at the Dana Farber Cancer Institute, tested a hypothesis
that physical deterioration resembling accelerated ageing in a
mouse strain with short, dysfunctional telomeres could be inhibited
by systemic amplification of telomerase expression. In these exper-
iments, a transgenic strain of mice was created from telomerase-
deficient animals to contain an expression cassette for the enzyme,
inducible by the drug 4-hydroxytamoxifen (4-OHT), an oestrogen
receptor agonist/antagonist used in therapy for cancer and endo-
crine disorders. In comparison with sham-treated mice, transgenic
animals administered 4-OHT as time-release pellets to reactivate
telomerase expression manifested dramatic reversal of the rapid
physical deterioration associated with the parent phenotype. Ampli-
fied telomerase expression in the transgenic mice restored physical
integrity and function of all tissues examined to levels expected in
young, healthy animals. These dramatic improvements in progno-
sis occurred despite the use of mice that exhibited physical deteri-
oration equivalent to extremely aged animals near the end of
lifespans expected for the telomerase-deficient strain. Of particular
interest was an observation that neural degeneration was com-
pletely reversed in animals engineered to contain a 4-OHT-induc-
ible somatic telomerase reactivation element, along with the
restoration of smell, reproductive capacity and liver function [14].
The dramatic effect of telomerase reactivation on apparent physical
age of mice used for these experiments is shown below in Figure 3.
Telomerase-deficient mice engineered to contain a 4-OHT-induc-
ible telomerase reverse transcriptase-oestrogen receptor (TERT-
OR) allele respond to stimulation with 4-OHT by reactivation of
telomerase activity and maintenance of telomere length along with
healthy function of tissues and organs. Mice not treated with
4-OHT exhibit low telomerase activity and rapid deterioration of
multiple cellular and organ functions expected as an outcome of
defective telomeres. Conversely, mice implanted with 4-OHT-releasing
pellets experienced somatic telomerase reactivation and significant
delay of progeric phenotype onset. Dramatic results of these
Fig. 2 Influence of young undamaged versus old or damaged cells on health and disease. Young, undamaged cells express products and perform
functions that contribute to healthy homeostasis. Old cells and damaged cells that have developed a senescent phenotype (stress-induced prema-
turely senescent, SIPS) affect surrounding tissue in ways that contribute to age-associated deterioration, including dysregulated inflammation and
cancer (Campisi, 2005; Hara et al., 2011). Source: Aging and Stress Group, University of Namur, Belgium.
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evaluations are shown below. Here, the 4-OHT-treated, telomerase-
enhanced, 48-week-old mouse on the left exhibits a physical age
apparently younger than the 35-week-old non-4-OHT-treated prog-
eric animal [14].
The relevance of these findings to vertebrate ageing remains to
be determined. Despite the enhanced cancer risk likely to be engen-
dered by telomerase-based ‘rejuvenation therapies’, it is tempting
to predict that results of the work at Dana Farber reveal a solid
mechanistic strategy for intervention in the normal process of age-
ing. However, at the time of this writing, such a conclusion would
be premature, especially since Jaskelioff et al. did not report a
favourable impact on lifespan as an outcome of their study. More-
over, the extremely high carcinogenic potential of telomerase aug-
mentation makes it unlikely that such an approach to age
intervention will become practical for human beings unless and
until more effective means of suppressing and/or treating cancer
have been developed.
Finally, observations reported by the Dana Farber group were
based on a highly specialized progeric mouse strain bred for short
telomere length and short lifespan. Hence, their findings should not
be extrapolated to other vertebrate models, including human beings,
until ongoing studies of telomerase amplification on normal ageing
begin to produce definitive data. The status of telomere integrity
and telomerase expression in a particular cell species influences its
pattern of gene expression (epigenomic profile), which is mani-
fested as cellular phenotype. Here, the term ‘epigenome’ refers to
gene expression profiles for any particular cell type, which define
its phenotype and homoeostatic role. Epigenomic profiles of cells
within a tissue develop in response to interaction between the inter-
nal makeup of a cell and its external environment. This, and many
other influences, create mosaics of cell phenotype within tissue that
ultimately act as major determinants of lifespan, as discussed in
section on shifting epigenomic profiles, below.
Major epigenomic profiles represented in tissue:
functional cell categories
Lifespan definition and major contributing factors
‘Lifespan’ for any particular animal, plant or cell, may be broadly
defined as the average length of time that the organism may resist
succumbing to environmental and internal stressors – in the absence
of disease, accident or other catastrophic events. The ability of an
individual to remain alive and functional is dependent at a fundamen-
tal level on the number and distribution of five major functional cell
categories, each defined by a unique epigenomic profile. These are
described briefly as follows:
I Regenerative mitotic (stem) cells: These are cells capable
of maintaining tissue integrity by proliferative response to dam-
age, including ‘progenitor’ stem cells, which are specialized
types of stem cell differentiated to a degree that allows them to
replace a specific type of tissue such as muscle cells or
neurons [24].
II Quiescent post-mitotic cells: These cells are healthy and ter-
minally differentiated to functional roles in which cell division is
not necessary. Examples include nerves [25], heart muscle and
other specialized tissue.
III Transformed cells (cancers): Cells that have undergone can-
cerous transformation represent the greatest drawback to
regenerative capacity of a particular type of tissue. A capacity
for tissue regeneration has given organisms that have it, such
as vertebrates, an enormous adaptive advantage over multicel-
lular life forms in which non-dividing cells constitute the pre-
dominant tissue [3]. However, proliferation-capable cells that
sustain non-lethal genomic damage in the form of somatic
mutations, often propagate this damage by dysregulated clonal
expansion [3]. In many cases, such damaged cells exhibit
destructive phenotypic characteristics that damage or kill the
host. This is the definition of cancer [26].
IV Senescent post-mitotic cells: Senescent cells are those
which are damaged in ways that disable their proliferative abil-
ity, but do not cause carcinogenic transformation or cell death.
The first stage of cellular senescence is damage-induced cell
cycle arrest, also called replicative senescence (RS). Typically,
Fig. 3 Inhibition of multi-organ deterioration in progeric mice by reac-
tivation of endogenous telomerase expression. Telomerase-deficient
mice engineered to contain a 4-hydroxytamoxifen (4-OHT)-inducible tel-
omerase reverse transcriptase-estrogen receptor (TERT-ER) allele
respond to stimulation with 4-OHT by reactivation of telomerase activity
and maintenance of telomere length along with healthy function of tis-
sues and organs. Mice not treated with 4-OHT exhibit low telomerase
activity and rapid deterioration of multiple cellular and organ functions
expected as an outcome of defective telomeres. Conversely, mice
implanted with 4-OHT-releasing pellets experienced somatic telomerase
reactivation and significant delay of progeric phenotype onset. Dramatic
results of these evaluations are shown below. Here, the 4-OHT-treated,
telomerase-enhanced 48 week old mouse on the left, exhibits a physical
age apparently younger than the 35 week old non-4-OHT-treated prog-
eric animal. From: Aging Ills Reversed in Mice”. Article by Gautam Naik,
The Wall Street Journal, November 28, 2010: Press release, Ronald
DePinho laboratory, Dana-Farber Cancer Institute in Boston, MA, USA.”.
Photograph by Dr. Mariela Jaskelioff, lead investigator.
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this growth arrest is triggered by stress-induced DNA damage
responses (DDR), and also may be induced as a result of effects
of telomere erosion – a phenomenon that produces stress-
related metabolites [27]. These influences activate tumour sup-
pressor genes, in particular the p53 and pRB pathways, in which
damaged DNA and other by-products of cellular stress interact
with constitutively expressed cytoplasmic precursors of tran-
scription factors, to form complexes that negatively regulate cell
division cycle (CDC) elements and halt proliferation [3]. These
cells may remain functional to some degree, depending on the
level of damage responsible for abolishing proliferative potential.
However, damaged cells in sustained replicative arrest typically
undergo a process called ‘geroconversion’, in which hallmark
phenotypic characteristics emerge that makes their presence
detrimental for the host [3, 27]. Geroconversion is a damage-
induced alteration in cellular homoeostasis that causes the emer-
gence of cell forms that adversely impact tissue function. DDR
activation resulting from oxidative damage to a cell hyperacti-
vates growth-promoting cellular process, especially the nutrient-
sensing complexes mTORC1 and mTORC2, which both include
the serine/threonine protein kinase mTOR. These complexes
respond to oxidative stress, systemic nutrient level elevation and
other cues to maintain high levels of cell growth-related gene
expression, especially in the presence of nutrients [27]. As this
input of gene products is not counterbalanced by cell division,
senescent cells assume a characteristic large, flat or distorted
morphology, and often accumulate high levels of pH 6-active
beta galactosidase, a lysosomal hydrolase up-regulated by an
overload of a cell’s degradative machinery as a result of high lev-
els of stress-associated detritus [3, 27, 28]. Senescent cells may
also express proteases and inflammatory mediators, such as
interleukin-6 (IL-6) that trigger unregulated and pathological
inflammatory processes. Accumulation of senescent cells
adversely affects their tissue microenvironment, contributing to
metabolic syndrome/type 2 diabetes, cancer and many other
age-associated disorders [3]. Conversely, deletion of senescent
cells delays the onset and reduced severity of age-related pathol-
ogies in mice [23]. Further demonstration of rapamycin-medi-
ated mTOR inhibition to enhance autophagic clearance of toxic
aggregates and mitigate severity of age-associated disease was
reported in October 2011 by researchers at the Institute of Clini-
cal Medicine at the University of Eastern Finland. These investi-
gators demonstrated that the restoration of autophagy by
rapamycin-mediated suppression of mTOR activity enhances the
viability of human retinal epithelial cells through clearance of
lipofuscin deposits [29, 30]. These results further underscore
the clinical potential of senescent cells as therapeutic targets.
Indeed, as suggested by the authors of the aforementioned
report, the results presented suggest the clinical value of a rapa-
mycin-based ophthalmic solution (eye drop) for the treatment
for age-associated macular degeneration [29].
V Cells executing a death program: Damage to a cell activates
several processes that may result in its death. Four major types
of cell death have been characterized at the time of this writing
[31]:
i Type I cell death/apoptosis: This is a tightly regulated pro-
cess activated by specific biochemical signalling cues, in
which a damaged cell is neatly dismantled in ways that avoid
random release of cell contents, thus avoiding tissue toxicity
[31, 32].
ii Type II cell death/autophagy: Autophagy (or ‘self-eating’)
is a process in which the internal components of the cell, in
particular, organelles and proteins, are enzymatically
degraded. Activation of the autophagic program may not
result in cell death, particularly if damage to the cell has not
been severe. In fact, under many conditions, it is an adap-
tive response to stress, particularly starvation, in which
degraded cell components may be re-utilized to promote cell
survival and restoration of healthy function [27].
iii Type III cell death/necrosis: This pathway typically occurs
in response to severe stressors imposed on tissue, such as
mechanical, chemical or thermal trauma, dysregulated
inflammation, microbial challenge and cancer. A major fea-
ture of necrosis is the uncontrolled release of cell contents,
which may subsequently initiate pro-inflammatory pathways
in ways that may become pathological [31].
iv Type IV cell death/‘necroptosis’: This process exhibits cell
morphological features very similar to necrosis, but also is
characterized by biochemical processes that are shared with
apoptosis, along with a unique temporal progression distinct
from both apoptosis and necrosis [31, 33].
Progressive shift in epigenomic profiles: a major
unifying feature of multicellular ageing
Integrating cellular and whole-organism features
Despite the complexity and seeming randomness of the ageing pro-
cess, studies of its cellular and molecular features have begun to
reveal a comprehensive picture of age-associated physical decline
that takes into account findings drawn both from work with cells in
culture and whole organisms. The health and viability of any multicel-
lular organism at all developmental stages, from embryonic to senes-
cent, is a function of the epigenomic profiles of its constituent cells
[34, 35].
The overall physical status of an organism, broadly defined as
health and viability, is completely defined by the relative representa-
tion of cells in the five major functional cell status categories
described above in Section I-2. Each of these categories represents a
characteristic pattern of gene expression constituting the epigenome
of a particular cell, establishing its phenotype and activity within a
particular tissue. Collectively, interacting cellular epigenomic profiles
are manifested as tissue and whole-organism health status. Ageing
may therefore be defined as the progressive shift in epigenomic pro-
files of cells that collectively make up an individual, and age-related
physical deterioration occurs as a function of how far these shifts
move an individual away from steady-state homoeostatic equilibrium
(representing ideal health).
Individuals with an elevated fraction of cells in a healthy quies-
cent post-mitotic state (Category II) are likely to exhibit balanced
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homoeostasis and good overall health. Likewise, organisms under-
going significant growth, in which large numbers of dividing cells
(Category I) are adding healthy tissue, may exhibit robust viability,
particularly if the cell growth is part of an existing developmental
program representing the transitional stages of early life. The via-
bility of an organism with high representation of Category I cells
may nevertheless be low if high rates of cell proliferation are
occurring in response to trauma. In such cases, elevated mitotic
activity may be an adaptive response, with the potential to restore
a physiologically compromised individual to its optimally healthy
state.
The presence of category III cells (cancer) is an obvious and
typically lethal disadvantage, even when the percentage represen-
tation of such cell species is low. Signalling pathways that result
in geroconversion into senescent cellular forms (Category IV)
effectively block carcinogenic transformation. Nevertheless, age-
or trauma-related tissue build-up of senescent cellular phenotypes
creates progressively toxic tissue microenvironments that favour
transition to cancer and other degenerative processes [3]. The
overall deleterious influence of senescent cells on whole-organism
viability is significant in normal ageing. Cells that have undergone
replicative arrest as result of both stress-induced damage and
telomere erosion (which constitutes a special kind of stress, as
will be discussed below), develop into senescent forms that accu-
mulate over time and become major contributors to age-associated
pathologies such as atherosclerosis, stroke and other chronic syn-
dromes characterized by dysregulated inflammation [3, 13, 27].
Role of cell death programs in tissue cell phenotype
representation
Of major interest in the context of the present review is the relative
representation of Category V – that is, cells that have been activated
to execute signalling pathways leading to death via apoptosis, auto-
phagy, necrosis or necroptosis. Each of these four major modes of
cell death is potentially useful in counteracting normal age-associ-
ated physical decline and maintaining the representation of cellular
phenotypes that maximize an individual’s retention of youthful char-
acteristics. The rate and magnitude of cell death occurring in a par-
ticular tissue establishes the distribution of cellular phenotypes and
effectively defines virtually all aspects of an individual’s physical
makeup at any given developmental stage and environment. It is
therefore likely that strategies for intervention in normal ageing will
become increasingly focused on methods for skewing representa-
tion of cells towards increased percentages of healthy, quiescent
forms, and where needed, healthy replicative or regenerative types:
cell phenotype categories I and II described in section I-2 above)
respectively. At the time of this writing, therapeutic methods that
skew cells in a particular tissue towards desired phenotypic repre-
sentation patterns have not been used specifically to target ageing
in human beings. Phenotypic skewing by selective induction of
death, versus survival programs within a tissue may nevertheless
become an increasingly important tool in life extension strategies
with increased understanding of molecular mechanisms leading to
cell death. An exploration of how oxidative stress contributes to
activation of the apoptotic death program is provided in Part II of
the present review.
Developmental shifting of cellular phenotypic representation
in tissue
Eukaryotic multicellular organisms begin as an undifferentiated plu-
ripotent stem cell, normally in the form of a single cell embryo, which
may proliferate with little differentiation to form a peri-implantation
embryo, or blastocyst. The component cells then undergo further pro-
liferation and differentiation to form an organism’s three classes of
progenitor tissue: endoderm, mesoderm and ectoderm. During early
life, each tissue contains proliferation-competent progenitor cells
(functional category Type I) in percentages that are elevated relative
to later developmental stages. These ‘oligopotent’ stem cells are
capable of terminal differentiation into specific types of tissue and
serve as a pool of reserve tissue to replace quiescent post-mitotic
cells (functional category II) as they become depleted through stress-
induced attrition. Cell damage which fails to move a cell into func-
tional category V through activation of a death program may cause
genetic changes, causing transition to functional category III (cancer).
Vertebrate eukaryotes have evolved a major anticancer adaptive pro-
gram followed by damaged cells, which causes their conversion into
senescent phenotypes (category IV), which are incapable of prolifera-
tion, but remain alive. Progressively decreasing percentages of quies-
cent and regenerative cells in tissues during adulthood through old
age are paralleled by increased representation of senescent cells [3].
At the time of this writing, although no direct mechanistic correlations
between cellular senescence and whole-organism ageing have been
established, the known effects of senescent cells on resident tissues
provide the basis for a compelling hypothesis. Specifically, a possible
explanation for physical decline that accompanies the chronological
age of an organism is that progressively elevated numbers of senes-
cent cells in each tissue adversely affect tissue integrity and function
in ways that are manifested as senescent whole-organism pheno-
types. Approaches to testing of this hypothesis in ways that may lead
to strategies for counteracting normal ageing are discussed in section
III-3 of the present review. A conceptual picture of an age-related shift
in representation of functional cell categories is shown below, in
Figure 4.
Tissue regeneration and cell death: tools for
modulation of age-related physical decline
Stem cell-mediated tissue regeneration strategies
Approaches that may be used in skewing modes of cell death in ways
that favour youthful representation of functional cell categories in
tissue will be discussed in section III-3 of this review. Below in the
present section, some of the approaches for augmenting a represen-
tation of Category I, healthy replication-competent (stem) cells will be
considered. One treatment that relies on such a process, bone
marrow transplantation (BMT), has a well-established track record in
clinical medicine. This method, which regenerates haematopoietic
tissue by supplementation with allogeneic stem cells, is discussed
below.
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BMT – an early, prototypic stem-cell therapy
The most widely used form of cellular regenerative therapy that relies
on repopulation of a tissue niche with Category I (mitotic) cells is
BMT. BMT, for reasons discussed below, has features that allow it to
serve as a very early prototypical model for stem cell-based rejuvena-
tion therapy. Nevertheless, BMT has never been used specifically as
an anti-ageing measure, and in its present form, it is not likely to have
direct application in any age-intervention strategies. BMT is a drastic,
invasive and painful treatment, typically used for patients afflicted
with neoplastic lymphoproliferative disorders (including leukaemias)
who have proven refractory to chemotherapy, radiation and other
commonly used anticancer regimens. Nevertheless, observations of
the behaviour of transplanted haematopoietic stem cells (HSC) help
establish guidelines for transplantation of a wide range of other pro-
genitor cell types. For example, recent studies demonstrating the abil-
ity of HSC from young mice to suppress cell senescence-related
biomarkers and rejuvenate renal tissue in aged mice [36], suggest
that BMT may provide a therapeutic paradigm of potential use in the
design of clinical protocols for counteracting physical ageing.
Preparation of a patient for BMT may involve complete ablation of
bone marrow, using whole-body radiation or chemotherapeutic
agents such as cyclophosphamide and busulfan. Although on a case-
specific basis, a ‘non-myeloablative’ protocol that leaves recipient
bone marrow in place may be used. The reduced level of trauma as a
result of treatment with this latter procedure is offset somewhat by an
increased risk of cancer relapse. A patient is then administered either
autologous or allogeneic cell preparations, which have high percent-
ages of HSC. These may be obtained from donor bone marrow or
from the peripheral blood of either a donor or the patient by a process
called apheresis, which extracts HSC from blood. The therapeutic
effect depends upon the ability of transplanted HSC to replace a
patient’s original haematopoietic tissue and provide the individual
with a self-renewing source of progenitors for each of the haemato-
poietic lineages.
A
B C D
Fig. 4 Development/age-related shift in
tissue representation of functional cell
types.
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Refinements in the clinical use of BMT have resulted in steady
improvements in its efficacy during the late 20th and early 21st centu-
ries. Nevertheless, the adverse effects associated with this procedure
underscore the dangers associated with the use of stem-cell trans-
plantation in broad clinical venues. The major complications of BMT
include several life-threatening conditions that develop as a result of
the method of applying this treatment, and also as a consequence of
stem-cell behaviour. The general immunosuppression that accompa-
nies the destruction of recipient bone marrow, along with the effects
of immunosuppressive drugs, leaves a patient vulnerable to opportu-
nistic infections and sepsis. BMT recipients are also highly suscepti-
ble to new malignancies that may arise from carcinogenic influences
on host tissue of marrow-ablative treatments. BMT carries an
additional risk of tumour evolution from transplanted HSC, as place-
ment in their new environment may stimulate dysregulated prolifera-
tive responses, including carcinogenesis.
Another major obstacle to successful BMT currently faced by
healthcare providers is the requirement for a close human leucocyte
antigen (HLA) tissue match between donor and recipient to avoid
graft-versus-host disease (GVHD), an often fatal syndrome resulting
from immune attack on host tissue by transplanted donor leucocytes
[37]. Typically, a prospective BMT recipient’s siblings are screened
for suitability of donors and failing this, the search is widened to unre-
lated persons. Nevertheless, at the time of this writing, a large per-
centage of patients requiring allogeneic HSC are unable to identify
matching donors [38].
Mesenchymal stromal cell influence on differentiation and
immunogenicity in bone marrow cultures
A rapidly evolving and very exciting strategy for increasing safety
and efficacy of BMT, with profound implications for sustained regen-
erative capacity of all tissues, is the use of mesenchymal stromal
cells (MSC), which were first identified as a subpopulation within the
bone marrow that may act as a ‘feeder’ cell layer to sustain HSC
function in vitro [39]. A major unique property of MSC is ‘multi-
potency’. That is, their interaction with tissue culture surfaces
stimulates differentiation into a wide variety of functional cellular
phenotypes, exhibiting ectodermal, endodermal and mesodermal epi-
genomic expression profiles [39, 40]. The potential for therapeutic
use of such phenotypic ‘plasticity’ by MSCs is augmented by their
negligible immunogenicity [41]. This property enables MSCs to
evade alloreactive cell recognition, thereby allowing their clinical use
without the requirement for donor–recipient HLA tissue match [39].
MSC are also observed to down-regulate T lymphocyte immune
activity [42], a property which offers enormous potential for their
application in the prevention and management of tissue damage
resulting from hyperactive inflammatory processes. Indeed, host
MSC are observed to reduce the risk and severity of GVHD in BMT
patients through the inhibition of T cell-dependent pro-inflammatory
processes [43], the recruitment of donor HSC to host bone marrow,
enhancing their engraftment and promoting haematopoiesis [39].
The foregoing observations reveal host-derived MSC to be a criti-
cal component for bone marrow regeneration and maintenance. How-
ever, the evolution of MSC-based preventive medicine and therapies
will require sustainable sources of allogeneic MSCs. Fortunately, MSC
lines derived from umbilical cord blood may be functionally expanded
in vitro to promote engraftment of progenitor stem cells capable of
regenerating a wide variety of tissues [39].
Placenta-expanded MSC product-1 (PLX-1) aids in engraftment of
HSC derived from umbilical cord blood (UCB). The first mainstream
medical application of UCB MSC was made by Pleuristem Therapeu-
tics of Haifa, Israel, which in 2008 obtained U.S. F.D.A. clearance for
Phase I clinical trials of a product called PLX-1 cells, which are pla-
cental-derived MSCs expanded ex vivo and stored frozen before being
administered to patients by i.v. injection [39].
Relevance of PLX-I and related MSC to age intervention
A major objective of Pleuristem and other parties developing alloge-
neic cell lines capable of enhancing representation of regenerative
cells in a particular tissue is to broaden the range of tissues into
which products such as PLX-I may be engrafted. Progressive refine-
ment of this technology may ultimately allow a sustained regimen of
treatments to continually regenerate a comprehensive approach that
facilitate achievement of this objective. A major outcome may
include maintenance of a healthy and balanced tissue homoeostasis
for very long time periods – which could be manifested as a pro-
longed lifespan. Such an outcome would also require simultaneous
protection against cancer and deletion of senescent cells. Consider-
ation of factors contributing to these objectives is discussed below.
Activity of mTOR in bone marrow
BMT offers a particularly good model for initial efforts to restore the
regenerative capacity of a representative tissue and prolong the time
period that it is stable and functional. Elevated representation of
senescent cells in the bone marrow of a recipient can adversely
affect the capacity of stem cells introduced via BMT to restore func-
tion and viability of haematopoietic [27]. As previously described, a
major contributor to the development of the senescent cellular phe-
notype is hyperactivation of nutrient sensor and growth pathways, in
particular mTOR and its derivative complexes mTORC1 and
mTORC2[3, 27, 28]. These findings suggest that age-intervention
strategies are likely to include pharmacological inhibition of mTOR
activity, an approach that will be discussed in Part 3 of the present
review.
In healthy bone marrow, or marrow successfully restored to
functional capacity by BMT, a pool of self-renewing ‘progenitor’ HSC
(Category I in section I-2 above) are distributed throughout the tis-
sue and maintained in a metabolically active quiescent state which,
in response to physiological cues, is capable of progression into the
cell cycle and production of blood components. During healthy HSC
proliferation, cell mass increases due to up-regulation of mTORC1
signalling keeps pace with cell division and cells of normal size and
function are produced. However, in a tissue environment which
favours potentially pathological levels of cell growth signalling,
mTORC activity becomes hyperactivated as a result of the critically
decreased availability of the major negative regulators of this enzyme
complex, resulting in the exhaustion and depletion of HSCs. Dysre-
gulation of mTOR is also observed to modulate the activity of the
enzyme in ways that promote enhanced mitochondrial biogenesis,
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with resulting increases in oxidative stress [44] and decreased dif-
ferentiation of HSC into cell forms that contribute to normal homo-
eostatic function. By contrast, the capacity of HSC to regenerate
functional blood cell lineages is dramatically increased by inhibition
of mTOR. As mTOR is a negative regulator of autophagic processes,
inhibition of this enzyme increases autophagy, resulting in clearance
of toxic debris and increasing autophagy and suppression of the
emergence of senescent cellular phenotypes [44]. These aforemen-
tioned outcome taken in context with demonstration of the rejuve-
nating effects of BMT from young mouse donors on aged mouse
kidney [36], underscore the value of BMT as an example of how
stem cells might be applied as a countermeasure to age-associated
physical decline.
Contribution of cell growth-promoting mechanisms to
cellular senescence
Hyperactivity of growth-promoting processes such as mTOR activity
is a major contributor to the toxicity of tissue environments that con-
tain a high representation of senescent cell types [3, 44]. This, and
other features of senescent cells, underscores the requirement to
counteract the influence of these cells – and if possible eliminate
them as an integral element of age-intervention strategies. Any
approach to rejuvenation-oriented skewing of functional cell types in
a tissue must consider how dysregulated mTOR hyperactivity and
other adverse influences of senescent cellular phenotypes, such as
their pro-inflammatory and carcinogenic effects [3], may affect
healthy cells.
Influence of senescent tissue environment on stem-cell
function
The effect of the tissue environment on stem-cell function is explored
in an elegant study by Irina Conboy et al. in an investigation of
progenitor stem cells for muscle, called myogenic satellite cells
(2005). This investigation revealed that myosatellite regenerative
function was significantly impaired in tissue from young healthy mice
that had been grafted into the senescent environment of aged ani-
mals. This investigation further revealed that the myosatellite regener-
ative and functional capacity was restored when tissue taken from
elderly donors was placed in younger recipients [45].
‘Parabiotic pairing’
A fascinating corollary experiment by these investigators demon-
strated that the rejuvenating effect of younger tissue on stem cells
from elderly individuals could be mediated by humoural factors.
These procedures made use of a technique called ‘parabiotic pairing’,
in which the circulatory systems of two syngenic mice were linked,
exposing the aged animal to the environment of the younger one and
vice versa.
Restoration of youthful competence to myosatellite cells in aged
mice was determined to have occurred due to reactivation of a sig-
nalling pathway called ‘Notch’, which declines in strength with age,
but is restored in the elderly member of a parabiotic pair through
mechanisms yet to be characterized. These findings, and analysis
of the effect of senescent tissue environment on HSC, clearly sug-
gest that the tissues of elderly individuals cannot be restored to
youthful vigour by simply introducing a new supply of progenitor
stem cells. It is likely that the functionality of these cells would be
rapidly degraded by the influence of resident senescent cellular
phenotypes. A possible countermeasure to senescent cell influence
might be the incorporation into genomes of progenitor stem cells,
to be administered therapeutically, of expression cassettes engi-
neered to produce activators for critical pathways such as notch.
The expression of such a signalling molecule might be made drug-
inducible, as was accomplished by the team at Dana Farber, who
constructed a 4-OHT-inducible cassette to increase telomerase pro-
duction in mice [14].
At present, however, such a strategy is highly speculative. More-
over, safety issues make such an approach extremely challenging.
For example, inflammatory cytokines (including IL-6) which may be
up-regulated in senescent cells by an anti-apoptotic protein HMGB1
are known to stimulate Notch signalling in ways that augment breast
cancers [46]. These observations underscore the need to consider
how a senescent environment may affect stem cells introduced as an
element of rejuvenation therapy – and how some future novel class of
stem cell programmed to express signalling pathway mediators may
endanger resident tissue.
Altering tissue cellular phenotypic ratios by varying
oxidative stress dosage: induction of apoptotic responses
versus senescence
Future strategies that are able to impart sustained youthful vigour
to whole organisms will almost certainly include methods for selec-
tively eliminating cell types that detract from the functional effi-
ciency of component tissues. In a broad sense, external stress
applied to cells, both in vivo and in vitro, achieves this purpose.
Varying the intensity of a wide range of stressors to which a tissue
or organism is exposed has been observed to reproducibly shift
the percentage representation of senescent cells, with those execut-
ing each of the four major pathways to death (apoptosis, necrosis,
necroptosis and autophagy). Relatively low stress levels favour pre-
dominance of senescent forms, followed by the induction of apop-
totic programs at higher levels, transitioning to necrosis when
stress levels become extreme [47].
Induction of autophagy and necroptosis
Cells which do not respond to oxidative stressors by senescence or
apoptosis may die via ‘necroptosis’, or undergo autophagy, which can
result in either cell death or survival under improved conditions of cel-
lular homoeostasis [31]. Cells are influenced to respond to various
stress conditions by a particular death or survival pathway depending
on the presence of certain pharmacological agents, or as part of
unique pathologies that may favour skewing of cellular activity pat-
terns into one of the aforementioned stress-response modes [31].
Cells may sustain a very wide variety of stressors, all forms of which
cause activation of DDR mechanisms, resulting in cell cycle arrest
and either senescence, repair and survival, activation of a death pro-
gram or carcinogenic transformation [3, 27]. Typically, DDR activa-
tion occurs as a result of a reaction between DNA and reactive
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oxygen molecules that cause strand breaks and production of DNA
degradation products which trigger cell cycle arrest through induction
of the ‘Gatekeeper’ tumour suppressive proteins p53 and pRB1/p16.
This either directly inhibits the transcription of genes needed for mito-
sis, or promotes the expression of other protein inhibitors such as
p21, the expression of which is driven by an interaction of p53 with
the p21 element’s promoter [3]. DDR activation hyperstimulates cell
growth mechanisms such as mTORC, which in turn promote the
development of senescent phenotypes and toxic tissue microenviron-
ments [27].
Cell stress: an epigenomic rheostat
Cellular consequences of DDR activation
The major common feature in virtually all influences that cause
stress-induced epigenomic changes is an interaction between a
cell’s DNA and reactive oxygen molecules produced by the stressor
– with resulting activation of DDR processes and conversion of the
cell from one of the phenotypic categories described in Section I-2
above into another [3, 27, 31]. Some stressors activate DDR with-
out DNA damage [48]. Therefore, within certain limits, manipulation
of external stress levels (including mild thermal stress, cold and
other influences that avoid significant cellular damage) potentially
provides a general approach for shifting epigenomic profiles in
ways that promote tissue and whole-organism vitality. By the fore-
going analysis, if stress levels delivered to a particular tissue can
be varied with some degree of precision, then differential applica-
tion of such stressors constitutes a biological rheostat. Ideally,
such an approach might be used to reproducibly vary the percent-
age representation of certain cell phenotypes, much as an electrical
rheostat is used to adjust the level of analogue signals on (for
instance) a light dimmer, or audio volume control.
Oxidative stress-mediated influence on components of the
nuclear cytoskeleton: relationship with progeria and normal
ageing
An example of how altering tissue oxidative stress levels may be used
to manipulate ageing-related cellular signalling is provided by the out-
come of the study that demonstrated how up-regulation of oxidative
stress by the drug 6-hydroxydopamine alters phosphorylation pat-
terns of the nuclear cytoskeletal proteins lamin A/C. Altered phos-
phorylation changes the interaction between this lamin and heat
shock protein-90 (hsp-90) in human neuroblastoma cells in ways that
correlate with the role of lamin A/C in age-related cellular and tissue
changes [49]. These results are particularly significant in the context
of the role of progerin, a mutant variant of lamin A, which adversely
alters nuclear scaffolding, causing disruption of cellular homoeosta-
sis, cell cycle arrest and rapid geroconversion into senescent cellular
phenotypes [27].
High expression of progerin has been identified as the cause of
Hutchinson-Gilford progeria syndrome (HGPS) [50]. HGPS-afflicted
human beings exhibit rapidly advanced rates of physical ageing, dying
at approximately 13 years of age from the same spectrum of disor-
ders, such as cardiovascular syndromes, which are typically the
cause of death in elderly human beings [50]. Sporadic expression of
a cryptic splice variant for lamin A also results in progressive accu-
mulation of the defective protein in cells of healthy individuals, thus
allowing the use of progerin as a reliable biomarker of ageing [51,
52]. Therefore, the aforementioned studies by Nakamura et al., dem-
onstrating the capacity of oxidative stress to act through nuclear lam-
in to affect age-related cellular biomarkers [49], increase the scope of
potential contribution of oxidative cellular processes to progerin-
related cellular and whole-organism senescence. Cells of the cardio-
vascular system are, for reasons not completely understood at the
time of this writing, particularly prone to disruption of cellular homo-
eostasis due to build-up of progerin and other toxic debris [50]. This
phenomenon may at least partly explain the observation that cardio-
vascular disease risk factors, including hypertension, hyperlipidaemia,
diabetes, insulin resistance, atherosclerosis and heart failure, increase
dramatically with age as contributors to mortality among the elderly
[53]. The effect of these influences may be mitigated somewhat by
short ischaemic periods interspersed with brief periods of reflow just
prior to reperfusion of cardiac tissue, which is a process called ‘is-
chaemic post-conditioning’ [54]. Characterization of mechanisms by
which cellular debris disrupts cardiovascular cell function in ways that
exacerbate risk factors and lead to disease is an area of ongoing
intensive research.
mTOR, autophagy and oxidative stress-related effects on
geroconversion: progerin-mediated
Research ongoing at the time of this writing has shown that the prog-
erin-mediated geroconversion of both HGPS and normal human cells
may be prevented and under some conditions reversed by induction
of autophagy through suppression of mTOR with rapamycin, an
mTOR-inhibitory drug [55]. In normal cells, mTOR activity sup-
presses autophagy thus allowing progerin and other cellular debris to
create oxidative damage resulting in cell cycle arrest and geroconver-
sion to senescent cell phenotypes [55]. For this reason, inhibition of
mTOR activity allows autophagic processes to occur at elevated rates,
causing ‘cellular housecleaning’ that clears progerin and other mis-
functional metabolic products to an extent that enhances healthy cell
function [27]. mTOR activity is strongly stimulated by oxidative stress
and inhibited by antioxidants [56, 57]. The ability of rapamycin to
inhibit mTOR and thus facilitate autophagic clearance of senescence-
inducing protein aggregates is potentially a very powerful tool in age
intervention. Nevertheless, the high toxicity of the drug makes it
impractical for its administration at dosages needed for sustained
suppression of senescent cell accumulation in a particular animal
[58]. Despite that, a strategy that makes use of a principle called ‘phy-
tochemical synergy’ may allow for substantial reduction in its effec-
tive dosage – and thus toxicity. These studies demonstrated that non-
toxic phytochemicals extracted from Ginkgo biloba were capable of
modulating calcium metabolism in ways that allowed the immuno-
suppressant FK506 to mediate powerful antiarrhythmic effects in a
rodent heart model at significantly lower dosage than FK506 alone
[59]. Similar strategies pursued in ongoing studies at University of
Debrecen may allow for reduction in the effective dosage and thus
toxicity of rapamycin.
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Cardiovascular ageing: why age-related physical decline
most often involves cardiovascular tissue
The effect of progerin and related protein aggregates in various cell
types yield insight into the reason cardiovascular pathologies are a
widely prevalent common feature of age-related physical deteriora-
tion. Mechanistic insight is provided by an observation that human
vascular cells express progerin. These cells are particularly suscep-
tible to disruption of cellular homoeostasis and deterioration in
healthy function [50]. Thus, in normal ageing, it is likely that
increased representation of cells bearing toxic protein aggregates
by all tissues will impact the cardiovascular system earliest and
most severely.
Recent studies by Rakesh Kukreja and colleagues at Virginia
Commonwealth University revealed that rapamycin constitutes a
particularly powerful countermeasure to cardiovascular ageing.
Using a murine model of myocardial ischaemia-reperfusion (I/R)
injury with isolated hearts in a Langendorff perfusion system, along
with parallel in vitro experiments, these investigators demonstrated
the ability of rapamycin to significantly protect whole hearts against
I/R injury, and further showed that the drug suppressed simulated
ischaemia-reoxygenation (SI/RO) damage to primary cardiac myo-
cytes. These studies revealed that the underlying mechanism
included activation of JAK2-STAT3 transcription factors, with a sub-
sequent cascade of cardioprotective signalling events, including
phosphorylation of ERK, STAT3, eNOS and glycogen synthase
kinase-3ß in concert with increased pro-survival Bcl-2 to Bax ratio
[60]. These outcome provide a basis for improved strategies for
prevention and treatment of cardiovascular disease in ways that
directly counteract degenerative changes occurring during the nor-
mal process of ageing.
The foregoing reports describe how oxidative stress may promote
accumulation of senescent cells through increased mTOR activity and
by adverse effects on cytoskeletal components such as lamins. A
picture emerges from the aforementioned, suggesting a strategy for
inhibition of age-related physical decline by promoting levels of auto-
phagy sufficient to enable ongoing disposal of toxic cellular products
such as progerin, but not high enough to cause significant autophagic
cell death. A major mediator in achieving such a balance is mTOR, the
variation in oxidative stress in particular, as a primary tool for manip-
ulating mTOR activity.
It is important at this point to qualify the above analysis by
emphasizing that such an approach could almost certainly never be
finely tuned enough to use it as a primary mechanism of rejuvenating
tissue – or a whole organism. The use of dietary antioxidants repre-
sents a popular, but poorly understood application of redox status
adjustment that is occasionally touted as ‘anti-ageing’ therapy. This
notwithstanding, selective use of antioxidants and possibly other
pharmacological agents will almost certainly have value in optimizing
conditions for the activity of stem cells that might be used for sus-
tained tissue regeneration approaches. As the purpose of this review
was to establish a solid molecular biological and cellular basis for
developing a general life extension strategy, Part II of the paper is a
comprehensive review of cellular redox sources of reactive oxygen
and how these molecular species interact with cell components to
either promote survival or activate a death pathway, with a focus on
apoptosis.
Reactive oxygen species (ROS) as
mediators of cell death – and cellular
phenotype representation in tissue
Oxidative stress, cell and tissue damage
As described above, oxidative stress plays a pivotal role in the age-
related deterioration of cells, tissues and whole organisms. Numer-
ous other human pathologies are characterized by oxidative tissue
damage. The most damaging of these are dysregulated inflamma-
tory processes in which symptoms resulting from tissue injury are
substantially mediated by highly reactive oxygen-containing mole-
cules that may be elevated systemically and/or locally at the site of
tissue injury. ‘Oxidative stress’, which broadly refers to the collec-
tive effect of these processes, may be caused by a wide range of
influences, including disease, drugs such as doxorubicin, mechani-
cal or thermal injury, and exposure to radiation or toxic chemicals
[61].
Reactive oxygen and apoptosis
Apoptosis
Apoptosis is a tightly regulated ‘suicide’ program, involving sequen-
tial dismantling of a cell’s structure proceeds according to a series
of steps designed to minimize the release of potentially harmful
products and provide for their efficient disposal. Superoxides and
related species have been implicated as major mediators of several
forms of apoptosis. For example, exposure of a cell to ionizing
radiation will cause the formation of high concentrations of hydro-
xyl (°OH) radicals as a result of radiolytic breakdown of water.
These react readily with DNA, protein and lipids to form nucleotide
adducts and lipid peroxides. The resulting damage activates the
cell’s apoptotic program [62]. A major objective in strategies to
inhibit age-related deterioration in tissue function is to identify criti-
cal redox signalling pathways that may be used to drive damaged
cells into apoptotic death as opposed to carcinogenesis or senes-
cence.
Carcinogenesis versus apoptosis
The role of ROS in both of these processes presents an apparent
paradox: in each case, elevated levels of ROS favour departure
from normal cellular homoeostasis, either to apoptotic death or
tumour formation. At the time of this writing, not enough is known
about the dynamics of either process to define the specific interac-
tions leading to one end or the other. One major juncture at which
a cell may either turn cancerous or die by apoptosis seems to be
dependent on the fate of PARP, which, responding to DNA broken
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ends acts to promote proliferation and (presumably) survival of a
cancerous line.
During apoptosis, PARP undergoes cleavage by the apoptosis-
associated protease CPP32/YAMA [63–65]. Presumably, if enough
CPP32-mediated destruction of PARP occurs before the action of
PARP tips the balance to proliferation, apoptosis will occur, abrogat-
ing a potential tumour. CPP32 is a critical element in this protective
process. If in fact superoxide-mediated inhibition of ICE occurs, then
PARP inactivation would be considerably reduced or absent in a
pro-oxidant tumour. A possible mechanism of oncogenesis involving
superoxide-mediated inhibition of CPP32 proteolysis of PARP can be
inferred from the known roles of both elements. CPP32/YAMA is a
member of a family of macromolecules that include the Interleukin-
1ß-converting enzymes (ICE), which are cysteinyl aspartate-specific
proteases, most commonly referred to as caspases, with activities
that constitute the core processes of apoptosis [66]. Two broad
classes of apoptosis-associated ICE have been characterized based
on their major role in the apoptotic process. These include the ‘initi-
ator’ ICE forms, which trigger apoptosis by cleavage of effector
caspases, thereby activating them to cleave substrates that include
cell structural components.
Pro-oxidant degradation of antioxidant defence
All cells studied thus far express very low constitutive levels of apop-
totic caspases and up-regulate the enzyme only when required for
apoptosis [67–70]. By contrast, other compounds bearing reactive -
SH groups are present at high concentration – including ROS scav-
engers such as glutathione (GSH), which are present at millimolar
levels [71]. How, then, might a situation arise in which sufficient con-
centrations of both O2
 and caspases are present such that the for-
mer might inhibit the latter by thiol oxidation, either at the catalytic
Cys or other Cys residues?
Such a phenomenon might develop as a result of defective O2

removal. As impaired function of superoxide dismutase (a specific
scavenger of O2
) is a hallmark of a wide variety of tumours [72],
high levels of superoxide production are expected, resulting in oxida-
tive stress and diminished antioxidant protection as a result of a
decreased concentration of GSH.
GSH as a pro-oxidant agent
This reduction in available GSH is a hallmark of the pro-oxidant state
[73], and may arise as a result of the reaction between high concen-
trations of O2
 with GSH. Under normal conditions (as previously sta-
ted), O2
 is dismuted primarily by SOD and does not interact
significantly with GSH. However, when defects in SOD processing of
O2
 allow its accumulation, it will react with GSH in a chain-propagat-
ing process which causes GSH to amplify oxidative stress rather than
dampening it [71]. Moreover, because O2
 is actually regenerated
during such a process, it is free to react with additional GSH or other
cellular components.
Apoptotic caspases regulate superoxide-induced apoptosis
The observations described above suggest that the phenomenon of
superoxide/thiol interaction, particularly where impaired SOD activ-
ity exists, substantially deplete GSH [64, 74, 75], and possibly thi-
oredoxin, leaving other cellular elements open to O2
 mediated
damage. Many potential targets exist, including (but by no means
exclusively) -SH and other reactive groups on caspases and their
precursors. Six major arguments may be offered for role of cas-
pase as a superoxide-sensitive target in abrogation of FAS-mediated
apoptosis under pro-oxidant conditions [76]. Each argument is
briefly summarized below:
1 Superoxide-sensitive cellular components must be essential
for FAS and TNF-dependant but not perforin/granzyme-mediated
apoptosis [77, 78].
2 The element which is inactive must be a ‘master switch’, that
is, its function is absolutely necessary for apoptosis.
3 Elevated levels of O2
 confer resistance to FAS-mediated
apoptosis, and reducing these levels restores FAS sensitivity
[79]. Hence, either O2
 itself or some product secondary to its
presence inactivates one or more elements critical for apopto-
sis. ICE (family) protease activity is critical for apoptosis and
ICE inhibitors also inhibit apoptosis [79].
4 Additional evidence that ICE family proteases constitute a
physiological ‘master switch’ for apoptosis, is provided by the
observation that CrmA, a general serpin inhibitor of the ICE
family will inhibit almost all forms of apoptosis. Upon compari-
son of the perforin/granzyme, FAS and TNF pathways, an ICE
protease (MACH) is vital for the two latter, but not the first
pathway. Moreover, Boldin et al. demonstrate that specific inhi-
bition of MACH will abrogate apoptosis [80–83].
5 MACH is the most upstream non-membrane-bound element
of the FAS (and) TNF pathways.
6 While it is true that concentrations of active ICE family prote-
ases are present at extremely low levels, their preformed pre-
cursors are present at constitutively higher levels. The reaction
of superoxide with solvent-exposed thiols (or other groups) on
these precursors might result in inhibition of active ICE forma-
tion, or the assembly of poorly functional ICE.
Superoxide-sensitive non-thiol groups on ICE and other
elements of cellular apoptotic pathways
Thiol groups on ICE proteases or its precursors are suggested as the
most likely targets for superoxide-mediated inactivation. However,
there is no reason that other interactions between superoxide and
components of ICE (or precursors) might result in an inhibitory effect.
As an example, physiological levels of hydroxyl radical (°OH) are
observed to react with tyrosine on some proteins, resulting in some
covalent modification (here the notation ‘°OH’ represents a hydroxyl
group with a single unpaired electron [84]).
Superoxide-mediated manipulation of cell fates
Caspase-superoxide interactions provide a paradigm for controlling
entry of a cell into a particular death program (apoptosis in the above
summaries). In addition, as depletion of GSH by superoxide corre-
lates with an onset or increase in superoxide-mediated caspase inhi-
bition, pharmacological alterations in the availability of this molecule
might be used as an additional measure of control for initiation of the
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apoptotic program. Many other features of the ROS-driven cell death
programs are potential targets for pharmacological control of cell
death and modification in tissue composition.
Countermeasures to age-associated
deterioration
Is the senescent cellular phenotype an
‘antagonistically pleiotropic’ ‘longevistat’?
Senescent phenotype: a cellular paradox
The preceding section provides an overview of how ROS interact with
critical regulatory molecules of the apoptotic pathway to induce cell
death. Caspases are a representative example. Many other molecules,
such as PARP, may also emerge as targets for modulation as part of
age-intervention strategies. However, the optimal use of this informa-
tion in skewing cellular phenotypic representation to compositions
that favour indefinitely sustained vitality of tissues – and whole organ-
isms – will require an improved understanding of cellular senescence.
The existence of senescent cells presents a fascinating paradox.
These cells are an example of an ‘antagonistically pleiotropic’ trait.
These confer an advantage early in life, but decrease the capacity for
survival with increasing age [22].
‘Good citizens and bad neighbours’
Senescent cells have been described as ‘good citizens’ as the emer-
gence of a senescent phenotype blocks a damaged cell from becom-
ing cancerous, but ‘bad neighbours’ as their accumulation creates
toxic tissue environments [3]. A major question posed by persistence
of these cells as a salient feature of all organisms that have a signifi-
cant tissue regenerative capacity is: ‘Why should the senescent
phenotype exist at all?’ Or more specifically: ‘Does the persistence
of these cells as tissue components following geroconversion
(defined as emergence of senescent phenotype) confer any particular
evolutionary advantage to a particular species?’ A speculative analysis
of their evolutionary role may be accomplished by considering alter-
native mechanisms for cancer prevention, which is the primary
advantage that senescent cells confer on an organism [3].
Evolutionary significance of senescent cellular phenotype
(an open question)
The conversion of damaged cells to senescent forms as opposed to
cancerous transformation is of obvious advantage, particularly during
early life when rates of cell division and tissue/organ growth are high
– offering enhanced opportunity for propagation of somatic muta-
tions. During this phase of development, the percentage representa-
tion of senescent forms is probably too low to significantly impair
tissue function. This developmental phase coincides with peak repro-
ductive proclivity, allowing expansion of a particular population [85].
What then, is the advantage to a species of accumulation of senes-
cent cells? One evolutionary alternative to senescence is activation of
an apoptotic response. Apoptotic deletion of lightly or moderately
damaged cells which is the stress intensity level favouring senes-
cence [47] would almost certainly have evolved if doing so were to
the advantage of a species – defined as size of a population of individ-
uals surviving through reproductive years. Indeed, as senescent cells
are deleterious to an organism, would not the disappearance of this
trait be a species benefit?
Certainly, reduced tissue representation of senescent cellular phe-
notypes would be advantageous to a particular individual. Accumula-
tion of these cells creates tissue environments that promote
dysregulated inflammation and cancer [3] and exhausts regenerative
capacity of progenitor stem cells [44]. Based on the comprehensive
picture of the biological role of senescent cells, it seems likely that an
evolutionary trend resulting in deletion of incipient cancer cells by
‘gatekeeper’ tumour suppressor functions such as p53/p21 and pRB/
p16 [3] would be sufficient to safeguard a species against pathologi-
cal propagation of somatic mutations – with cancer as a major out-
come. Again, the question arises: ‘What advantage does persistence
of the senescent cellular phenotype have for a particular species?’
One possible answer is that the major evolutionary role of senes-
cent cells is to limit the lifespan of a particular organism within a spe-
cies. Their absence might contribute to longer individual lifespans, as
a major effect of these cells is to limit the regenerative capacity of
progenitor populations [44]. Whether depletion of senescent forms in
a particular organism would allow increased lifespan is highly specu-
lative. However, at the time of this writing, insight into how develop-
ment of senescent phenotypes may be blocked and even reversed is
promising and will be discussed in the next section.
The evolution of a longevistat, whether cellular senescence or
some other trait, would only occur if there is a general selective
advantage for it. Some arguments can be made that limits on lifespan
for members of a particular species would favour expansion of its size
over time. But equally valid arguments can be made that survival of a
core group of very long-lived individuals would be enormously benefi-
cial for a species. This is certainly true for human beings. These argu-
ments are speculative and will inevitably become highly political if
age-intervention technology becomes available.
If indeed, senescent cell forms limit the lifespan of an individual,
then this cellular phenotype constitutes a true ‘longevistat’ – and
therefore becomes a priority target for age-intervention research. The
question of whether senescent cellular phenotypes have evolved to
limit individual lifespan for the benefit of a species will undoubtedly
remain a subject of debate for a long time. It is nevertheless clear that
persistence of these cells is detrimental to an individual once their
major protective function, cancer prevention, has been accomplished.
Accordingly, a major research direction will include strategies for
eliminating senescent cells as they form and replacing them with
healthy tissue.
Contribution of toxic aggregates to
proteinopathies, progeroid syndrome and ageing
Insight into how senescent cellular phenotypes form and strategies
for suppressing their development and pathological features have
come about as a result of investigations into the molecular mecha-
nisms of progeroid diseases, which are disorders that resemble
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accelerated ageing. As described in Section I-5 of the present review,
a progeroid syndrome of particular interest in oxidative stress-medi-
ated manipulation of age-associated tissue epigenomic profiles is
HGPS. Its major symptoms resemble physical manifestations of age-
ing, including wizened appearance/wrinkling and other age-related
physical deterioration. Death typically occurs as a result of heart fail-
ure or stroke, with accompanying atherosclerosis and other cardio-
vascular disorders at about age 13 [86]. Cells from HGPS-afflicted
individuals express high levels of progerin, a mutant form of the
nuclear envelope-associated intermediate filament prolamin A, which
also accumulates in normal, non-HGPS persons with advancing age.
Progerin activates signalling pathways (including DDR kinases) that
profoundly disrupt cell structure and homoeostasis, causing short-
ened telomeres and rapid progression to cell cycle arrest followed by
hyperactivation of mTOR and geroconversion into senescent forms
[87].
mTOR inhibition promotes autophagy, and suppresses
cellular senescence
Presence of cellular debris and damaged organelles stimulates auto-
phagic activity at rates sufficient under some conditions to restore
cell viability. But oxidative damage, or particularly deleterious mutant
proteins such as progerin promotes DDR activity at high levels,
causes hyperactivation of mTOR, which suppresses autophagy,
allowing damage and debris to stimulate emergence of the senescent
phenotype [27, 87]. Remarkably, the drug rapamycin (sirolimus)
inhibits mTOR activity to levels allowing for reconstitution of a cell’s
autophagic capacity, clearance of progerin and other debris and pre-
vention or reversal of geroconversion in cells from HGPS patients
[44, 88], and also in non-HGPS mammalian cells [89]. mTOR is thus
a major contributor to cellular senescence and to whole-organism
ageing due to its geroconvertive ability; moreover, inhibition of mTOR
allows enhanced autophagic degradation of toxic aggregates accumu-
lating in the cell [90, 91].
Autophagic contribution to resolution of neurodegenerative
disease
Intracytoplasmic accumulation of toxic aggregates are the primary
cause of several major neurodegenerative syndromes, including tau-
opathies, Parkinson’s, Huntington’s chorea, Alzheimer’s disease and
other ‘proteinopathies’ in which intracellular oxidative stress and
subsequent tissue inflammation results from disruption of normal
cellular homoeostasis by toxic aggregates [92]. Thus, therapies
which stimulate autophagy through mTOR inhibition are potentially
of widespread use in therapy for serious chronic diseases [28].
Value of autophagy in suppression of cellular and whole-
organism senescence
The aforementioned effects clearly establish autophagy and drugs,
such as rapamycin which promote it, as valuable tools for preventing
accumulation of senescent cells – in contrast to the role of autophagy
in some settings as a cell death mechanism [27]. The inhibitory effect
of rapamycin on ageing of mammalian cells in vitro, through augmen-
tation of autophagy, has proven valid in other models, both cell cul-
ture and whole organism, and has been shown to extend lifespan in
yeast [93], Caenorhabditis elegans [94], Drosophila [95] and mice
[88]. Moreover, both animal model and human clinical studies show
that the drug inhibits atherosclerosis, which is a primary symptom
and major cause of death among both progeric and normal elderly
human beings [96–98].
Significance of progerin to studies of normal ageing
A major challenge posed by use of progeroid models to design
strategies for countermeasures against normal ageing is defining
the role of progerin. All investigations of this molecule show it to
be a major mediator for emergence of the kinds of senescent cellu-
lar phenotypes observed in both HGPS and normal mammalian
cells [27]. It is, therefore tempting to predict that blocking develop-
ment of this mutant lamin may prove to be a significant tool in age
intervention. Nevertheless, the processes by which progerin contrib-
utes to cellular senescence and accelerated whole-organism ageing,
may not be a unique characteristic of this molecule, but a general
feature of many kinds cellular debris capable of disrupting structure
and function of cells.
Hypothetical model of age-associated physical
decline and proposed countermeasures
The foregoing analysis suggests that the fundamental cellular basis
for age-associated physical decline may closely resemble proteinopa-
thies underlying neurodegenerative disorders [92] and that treat-
ments that retard accumulation of such debris (such as augmenting
autophagy through suppression of mTOR) represent potentially pro-
ductive age-intervention strategies [27, 85].
Aggregate accumulation model of ageing
The concept of age-associated physical decline occurring as a result
of a progressive accumulation of cellular damage is not new. The
novel features of research into the ageing process explored in the
present review are considerations of how senescent cellular pheno-
types emerge and adversely affect homoeostasis as these cells
become represented at increasingly higher percentages in tissue.
According to the proposed model, physical ageing occurs as a conse-
quence of five fundamental processes:
I Cellular damage. Typically, this damage takes the form of
extracellular trauma resulting in increased levels of oxidative
compounds inside cells. It may also occur due to telomere
deterioration or activation of the ras oncogene, which inter-
nally increase oxidative stress and damage to cellular compo-
nents.
II Activation of damage response programs. Oxidative and other
damages activate programs that include major anticancer safe-
guards through p53- or pRB1/p16-mediated cell cycle arrest.
These programs nevertheless promote hypersecretory pro-
cesses such as mTOR, resulting in further toxic aggregate
accumulation and emergence of senescent cells.
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III Senescent cell accumulation. Senescent cells degrade sur-
rounding tissue and decrease whole-organism viability. More-
over, the selective elimination of these cells in a progeroid
mouse model delays the onset of age-related pathologies and
reduces the severity of established diseases [23].
IV Increased risk of cancer and inflammatory disease. A major
and progressively increasing effect of senescent cell accumula-
tion is that expression of pro-inflammatory humoural mediators
by these cells and their direct interaction with surrounding tis-
sue dysregulates inflammatory processes and also promotes
carcinogenic transformation [3].
V Decreased stem-cell effectiveness and depletion. Senescent
cells inhibit the capacity of stem cells to regenerate tissue func-
tion and decrease tissue representation of both stem and
healthy quiescent cells [44].
Obligate requirements for age intervention
Any medical treatment capable of affecting age-related physical
decline must alter tissue cellular profiles as defined in criteria i – iv
below.
Tissue cellular composition profile criteria
Effective age-intervention strategies must result in a stable alter-
ation in tissue composition of functional cell categories described
in Section I-2 of the present review that meet the following crite-
ria: (i) Elevated representation of stem and healthy quiescent cells
(Categories I and II respectively); (ii) No representation of cancer
cells (Category III); (iii) Minimal-to-negligible representation of
senescent cells (Category IV); and (iv) Representation of cells exe-
cuting death programs (Category V) in ratios that maintain the
stability of the aforementioned optimal cellular phenotypic profiles.
Role of telocytes in development of age-intervention strategies
The present review has considered how skewing the representation of
various cellular phenotypes within a tissue in favour of healthy quies-
cent or progenitor stem-cell populations may allow sustained tissue
function for long, perhaps open-ended, time periods. The foregoing
analysis has nevertheless not until this point taken into consideration
the influence of telocytes (TC), which are cell species that only
recently have been recognized as potentially critical to enabling pro-
longed maintenance of tissue regenerative capacity and normal ho-
moeostasis [99]. These cellular phenotypes were discovered and
named by Professor Lauren iu M. Popescu’s research group at Carol
Davila University in Bucharest, Romania [99]. They were shown to
exhibit ultrastructure and immunophenotype characteristics distinct
from other components of the interstitium (stroma), such as poly-
morphonuclear leucocytes, mast and mesenchymal cells and fibro-
blasts [99–101]. Telocyte morphology typically includes a very small
cell body containing the nucleus and a small volume of cytoplasm,
from which several tubular projections called telopodes extend up to
several hundred lm from the body, interfacing with immune, vascu-
lar, muscle and neural tissue in a three-dimensional network which is
increasingly demonstrated to maintain local homoeostasis of a partic-
ular tissue through coordination of intracellular communication [99–
101]. Ongoing investigations are revealing increasingly important
roles for TC in the stabilization of healthy tissue function so as to min-
imize inflammatory tissue damage to particular organs. For example,
Zhao et al. reported inverse correlation between the magnitude of in-
fracted zones of rat myocardium and cardiac telocyte density [102].
Telocytes, therefore, function in tandem with stem cells in anatomical
locations designated ‘stem-cell niches’, resulting in an enhancement
of their engraftment capability [103].
Isolation of TC and comprehensive structural and functional char-
acterization of these cells is made challenging by their diffuse and
intimate association with resident tissue and stroma. Nevertheless,
development of protocols for augmenting engraftment of progenitor
cells by manipulation of telocyte activity is a strategy which may
become critical for prolongation of healthy tissue homoeostasis. One
strategy for accomplishing this objective without requiring purified
preparation of TC are dose–response experiments in which electron
microscopy, immunohistochemistry, immunofluorescence, time-
lapse videomicroscopy and whole-cell patch voltage-clamp-based
assays were used to describe ultrastructural, immunohistochemical
and electrophysiological characteristics in human myometrium [104].
Related investigations undertaken to assess drug effects on telocyte
function often include dose-response studies in which agents such
as sildanafil, known to enhance stem cell engraftment [105] are
evaluated for correlations between drug dosage, progenitor cell stabi-
lity within a tissue and telocyte functional and phenotypic characteris-
tics as described by Cretoiu et al. [104]. Such experiments would be
best structured to use tissue models in which TC have been previ-
ously studied, combined with drug treatments known to improve pro-
genitor stem-cell engraftment stability. Using this general approach,
insight will be gained that allow drug combinations to be optimally
configured to affect telocyte function in ways expected to contribute
to tissue conditioning in development of age-intervention protocols.
The foregoing findings and experimental strategies underscore
the role of TC as a kind of MSC. This capacity is particularly relevant
to development of strategies in which commercially available MSCs
such as PLX-I are used as an approach to stabilize engrafted progeni-
tor cells into a wide range of tissue, concurrent with depletion of
senescent forms, with the objective of prolonging regenerative capac-
ity of a particular tissue. Indeed, as both TC and MSC may share a
wide range of overlap in tissue function, the combined effect of PLX-I
and telocyte activity may prove to be a very powerful approach to sta-
bilization of engrafted progenitor cells in many tissues. This possibil-
ity is explored in the following section, which proposes strategies for
sustained skewing of cellular profiles of a tissue as an element of life
extension.
Theoretical methods for achieving stable tissue cellular
profiles
The following prediction of a general approach for meeting the above
five tissue cellular composition criteria is highly speculative. More-
over, some of the specific methodology suggested in the five method-
ological features described below is not currently practical. However,
each method relies on increasingly sophisticated technology available
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at the time of this writing – and may become practical based on rap-
idly evolving understanding of the relationship between the activity of
cells in tissue and whole-organism physical status. Currently, an opti-
mal age-intervention treatment will likely include the following seven
major features:
I Establishment of a stable niche in each tissue for enhance-
ment of progenitor stem-cell engraftment. Creation of such
niches requires that stromal matrices for each tissue be
enhanced with respect to their capacities to allow stable
engraftment of immigrant progenitor cells. The cellular makeup
of stroma varies from tissue to tissue. For example, polymor-
phonuclear leucocytes Pleuristem PLX-I cells currently offer the
best commercially available choice for ready availability of pre-
cursors to these cells from umbilical cord blood and ease of in
vitro expansion, along with their non-immunogenicity and
immunoregulatory properties [39]. Three technical challenges
must be overcome before a PLX-like product may be used to
simultaneously alter the stromal environment of multiple tissues
as part of a life extension protocol. First, before PLX, similar
products may be used in this manner; strategies must be devel-
oped to improve targeting of selected PLX (or other MSC) vari-
ants into selected tissues. Precedents have been set by
Pleuristem and affiliated clinicians in PLX-1-augmented restora-
tion of haematopoietic capability of bone marrow for BMT
patients [39]; however, to use a family of PLX products as a
general mediator of tissue regeneration for all tissues in an
organism, an integrated array of PLX products and protocols
must be developed. Development of these protocols should
assess the impact of PLX infusion on telocyte density within a
particular tissue, as described by Zhao et al. [102] and where
possible, use outcome to optimize PLX treatment parameters.
II Periodic replenishment of oligopotent progenitor stem cells.
An essential requirement for age-intervention methodologies
based on directed skewing of cellular tissue profiles is a stem
cell capable of migrating to a variety of tissues in the body and
undergoing differentiation into progenitor forms for each tissue.
Where possible, autologous progenitor cells or multi-potent
allogeneic cells capable of migrating into selected target tissues
may be administered. Second, protocols must be developed for
vectoring progenitors of specific tissues efficiently into those
tissues.
III Cancer-suppressive components. This safety feature is
essential, based on the use of novel stem-cell lines as the basis
for replacement of progenitor stem cells. Alterations in the pro-
liferative potential of the stem-cell line from which the therapeu-
tic stem cells were derived may significantly enhance the risk
of cancer. One approach to the elimination of tumours arising
from the therapeutic line is to create it to be transgenic for a
gene product capable of inducing a cell death program, with
apoptosis being the optimal result due to the benign interaction
between its products and surrounding tissue (as opposed to
necrosis which may be pro-inflammatory). The transgenic
manipulation needed to accomplish this is carried out routinely
at the time of this writing, with an example provided by the
work of researchers at Dana Farber who created mice with
genomes containing expression cassettes for the telomerase,
inducible by the drug 4-OHT [14]. In a similar manner, a drug-
responsive element capable of expressing a pro-apoptotic gene
product would be inserted into the age-intervention stem cell. If
this were combined with insertion of a constitutively expressed
biomarker ‘tag’ element similar (for example) to prostate-spe-
cific antigen (PSA), a person could be monitored for precipitous
increases in the biomarker and treated with the inducer if such
increases occurred. This basic strategy would necessarily
require elaboration in the form of backup inducers of cell death
programs, alternate drug-inducible expression cassettes and
other refinements that would potentially create a safe, effective
and versatile stem-cell line capable of providing ongoing tissue
regenerative capacity, with minimal risk of stem cell-derived
cancer.
IV Enhancement of autophagy at levels sufficient to retard gero-
conversion of (all) cells. If a major underlying cause of cellular
senescence is accumulation of toxic aggregates, then strategies
that augment autophagy will contribute to the overall effect of
the age-intervention therapy on tissue. Here, it is prudent not to
rely on a single approach to enhance clearance of toxic cellular
aggregates. For example, although rapamycin may suppress
geroconversion through mTOR inhibition and a resulting amplifi-
cation of autophagy [27], administering high doses of this drug
in conjunction with other elements of the age-intervention pro-
gram described above is unlikely to be beneficial and would
likely be toxic to the patient. Optimal clinical implementation of
the proposed program might include subtoxic doses of rapamy-
cin, along with other inducers of autophagy such as sirtuin
enzymes. Sirtuins may be induced by dietary caloric restriction
and the grape polyphenol resveratrol [106]. Their increased
activity suppresses mTOR and up-regulates autophagy [27, 85].
Hence, several relatively benign treatments may be given to a
recipient along with low-dose rapamycin and the aforementioned
stem-cell therapy to maintain and enhance tissue viability.
V Modulation of oxidative stress levels to achieve desired bal-
ance of cell death program activation: Use of oxidative stress
as a cell death ‘rheostat’. As previously described, if the inten-
sity of oxidative stress to which a particular tissue is subjected
is altered, the cellular makeup of the tissue also changes. For
example, increased oxidative stress levels influence elevated
rates of necrotic, apoptotic and senescent cells [47]. This phe-
nomenon theoretically provides a way to ‘sculpt’ tissue compo-
sition by varying oxidative stress on a tissue in ways that
produce death responses towards desired ratios of cells in
apoptosis, necrosis, necroptosis or autophagy, depending on
the intended tissue representation of various cell types. A typi-
cal example of this strategy might include the use of a drug
such as 6-hydroxydopamine which increases oxidative stress
on tissue [49], administered in conjunction with sour cherry
seed biflavones, a treatment that has been shown to powerfully
inhibit oxidative stress [107]. Herein are the elements of a
‘rheostat’ for adjusting the representation of each cell death
program in a particular tissue. Ongoing in vitro, animal and
human trials are expected to reveal the dosage combinations
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that will produce desired ratios of each death program, allowing
increasingly precise tissue engineering.
VI Depletion of senescent cell phenotypes. The augmentation of
tissue with potentially rejuvenating populations of stem cells
will be only minimally effective if progressively increased num-
bers of senescent cells counteract their beneficial effects. This
constraint on stem cell-based age-intervention therapies is
underscored by studies at the Mayo Clinic College of Medicine
showing profound attenuation of age-related physical decline in
progeroid mice due to elimination of senescent cells [23]. For
this reason, it is desirable to deplete tissue of senescent cell
phenotypes wherever possible. Success of the aforementioned
investigation was made possible by designing a transgenic
mouse strain in which a critical signal to initiate the develop-
ment of cellular senescence activated a death program in the
presence of a drug inducer. Such a targeting strategy is obvi-
ously not applicable to a clinical setting. The objective of the
selective ablation of senescent cells, therefore presents some of
the same challenges as selective targeting of tumours. Similar
to cancer, senescent cells are derived from host tissue and thus
not subject to immune deletion – although some of their fea-
tures may be useful in developing immunotherapeutic counter-
measures against them. Fortunately, unlike malignancies,
senescent cells are tolerated by the host for long periods of
time, exerting their detrimental effects in a dose-responsive
manner manifested as the major symptoms of ageing.
VII Limitations on characterization of cellular phenotypic profiles
in ageing tissue. Ongoing characterizations of the senescent cel-
lular phenotype are likely to yield progressively improving target-
ing strategies against these cells – that are likely to become
major components of age-intervention programs. Such research
has nevertheless been constrained by the lack of an animal model
in which phenotypic representation of cells in tissues of an indi-
vidual become skewed in ways capable of counteracting age-
related physical decline. Recently, however, work by several
investigators, notably Kubota et al. at the Seto Marine Biological
Laboratory at Kyoto University, have demonstrated remarkable
properties of hydrozoans and related marine organisms that are
proving to be an increasingly important tool for dissecting the
age-related cellular kinetics of a potential use in design of tissue
regeneration strategies in vertebrates [108]. A summary of this
evolving research is provided below:
Reversible ontological progression in cnidaria: a unique
animal model for sustained tissue regeneration
Approaches designed to significantly mitigate age-related physical
deterioration are likely, within limits, to mimic an adaptive strategy
utilized by several species within the phylum Cnidaria, which include
free-swimming jellyfish and sessile polyps. Some of these animals
have evolved a unique regenerative process that enables an individual
to undergo a complete reversal of ontological development in
response to potentially life-threatening environmental stressors and
also to sexual maturity, which marks the onset of whole-organism
senescence [109]. The ability to regress into an immature form from
which the adult may regenerate, allows the animal to evade death
resulting from some kinds of external threats and also from age-
related deterioration following sexual maturity. One interesting theo-
retical consequence of this phenomenon is that individual animals
able to avoid death by predation, accident or disease might live for
very long time periods. At the time of this writing, the question of
whether median life spans for these species are truly open-ended has
not been definitively answered, but has become the subject of
increasingly intense investigation.
Particular interest is currently focused on correlation between a
hydrozoans’s longevity potential and circadian timing of spawning
activity [109]. Spawning behavior exhibited by many Cnidarian taxa,
includes stages in which sexually mature adults spawn larvae that
may affix to a stationary object to form colonies of polyps. Immature
adult (medusa) forms are released from the surface of polyps as buds
which grow into mature (medusa) forms, which when sexually
mature, mate and perpetuate the cycle [109]. The RD program is acti-
vated in a medusal form (either immature or adult) by external stress
or in adults by senescence-associated physiological deterioration fol-
lowing sexual maturity. The RD process in adults is very dramatic and
includes shrinkage of tentacles to bud-like appendages, redistribution
of major anatomical features and contraction of the entire organism
into a ball-like stage, which may the affix to a stationary object, form-
ing appendages called stolons from which a new polyp colony may
emerge [109].
The cellular signalling mechanisms underlying RD remain
poorly defined. It is known that the process is dependent on a
highly specialized form of metaplasia, which is a stress-response
pathway in which the cellular composition of a tissue changes to
meet novel environmental challenges [110]. Metaplasia is a process
widely distributed in the animal kingdom. A well-known example in
higher vertebrates is the reaction to cigarette smoke of stem cells
resident in airway connective tissue, which are stimulated to differ-
entiate into stratified squamous epithelium, which replaces ciliated
pseudostratified columnar respiratory epithelial cells [111]. Such
changes in tissue function arise as a result of stress-related signal-
ling cues acting to terminally differentiate progenitor stem cells for
a particular kind of tissue.
Tissues of sexually mature, RD-capable Cnidarians contain cells
which respond to environmental and internal cues by regression into
less terminally differentiated sexually immature forms, which collec-
tively develop into polyps, or immature form of the animal which is
physically ‘young’ and may regenerate the adult form [110]. These
remarkable organisms are the only known examples of metazoans
capable of potentially extending longevity by a cellular process termed
‘transdifferentiation’ that results in complete reprogramming of dip-
loid cell differentiation into a primitive form resembling embryonic or
foetal tissue, capable of developing into an adult – in essence living a
new life. Regeneration of RD-capable adults from polyps may not,
however, precisely represent sustained long life of a particular individ-
ual. With the exception of a few founder cells from which the new
polyp develops, the adult does not survive as a distinct individual. Tis-
sue turnover is essentially total.
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Jellyfish, stem cells and human beings
Analysis of the human ageing process using a cnidarian model would
for the purpose of most parameters be considered ‘ambitious’. Never-
theless, the age-intervention strategy proposed above in Section III-3
makes use of the most important underlying feature of the Turritopsis
nutricula survival paradigm. Individual T. nutricula animals maintain
their diploid genetic identity by periodically regenerating the entire
organism from specialized cells that have transdifferentiated into an
early juvenile state. At its most fundamental level, this is exactly the
course of action proposed in Section III-3 as a hypothetical ageing
countermeasure. If autologous stem cells are used as the basis for
such a countermeasure, some degree of transdifferentiation into a
more primitive form will be necessary. If at some point the technical
challenges to apply proposed process are met, regeneration might be
accomplished with retention of the physical integrity of an individual.
Senescent cells would be ablated (ideally) and healthy tissue (includ-
ing progenitor stem cells) would be continually replenished by infu-
sion of the yet-to-be-created ‘Trinity’ cell. The term ‘Trinity’ as used in
the present context, refers to the functional characteristics of a syn-
thetic cellular phenotype genetically altered to respond to drugs or
varying levels of oxidative stress by activation of signaling processes
that lead to death or survival via three major outcomes, defined by
apoptosis, necrosis or autophagy – with intermediate pathways such
as necropoptosis [31, 33] also represented as potential outcomes.
The proposed ageing countermeasure strategy is speculative. How-
ever, with certain refinements, this basic plan may be workable, based
on its reliance on technology which is either currently available or
likely to emerge in the foreseeable future.
Conclusions
Recent advances in stem-cell technology, together with a better
understanding of mechanisms by which oxidative stress activates the
cell death programs, apoptosis in particular, has allowed for the
development of a framework for defeating the normal ageing process
that may prove workable. A specific clinical method for counteracting
an age-related physical decline must alter the cellular composition of
an organism’s tissues in ways that meet three major criteria: First, an
organism’s pool of progenitor stem cells must be continually replen-
ished. Second, replacement stem cells must be capable of migration
to, and establishment in each of the body’s tissues in a configuration
that minimizes the risk of stem cell-associated cancer. Third, the
emergence of senescent cells and their activity must be suppressed.
As described in Section II of the present review, the evolving under-
standing of known mechanisms leading from oxidative stress to acti-
vation of particular cell death programs has allowed development of
strategies by which externally applied stressors may reproducibly
skew the death/survival programs execution by cells within a tissue
towards apoptosis, necrosis, necroptosis or autophagy. The result
has been the development of a broad strategy, which may be termed
‘necroapoptophagy’, in which tissue may be ‘sculpted’ by the differen-
tial induction of each of the four aforementioned programs leading to
cell death (or restoration of healthy cellular function as a potential
outcome of autophagy). As laboratory and eventual clinical use of
necroapoptophagy becomes increasingly sophisticated and precise
in achieving the desired tissue cellular profiles, clinically useful
strategies for counteracting normally occurring physical ageing may
emerge.
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